Diterpene synthase and application thereof

By identifying and utilizing new diterpene synthase, the biosynthesis of tristinane diterpene compounds was achieved, solving the problems of limited sources and difficult chemical synthesis, and providing efficient and environmentally friendly drug synthesis methods.

CN119020337APending Publication Date: 2024-11-26INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310613190.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The tristinyl diterpene compounds have limited sources and low content, difficulty in chemical synthesis and environmental pollution, and lack of biosynthesis research, which limit their drug development and application.

Method used

A new diterpene synthase was discovered and functionally identified, and its amino acid sequence has the activity of catalyzing the generation of diterpene compounds. The diterpene synthase was prepared through nucleic acid molecule expression vector and host cells, which was used to catalyze the biosynthesis of trisine sane and other di Terpene compounds.

Benefits of technology

The biosynthesis of high-efficiency synthesis of tristinyl diterpene compounds such as Hainan rutrelactone has been achieved, avoiding the poor stereoselectivity of chemical synthesis and environmental pollution problems, and providing new methods for drug research and development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004253090900000041
    Figure BDA0004253090900000041
  • Figure BDA0004253090900000071
    Figure BDA0004253090900000071
  • Figure BDA0004253090900000111
    Figure BDA0004253090900000111
Patent Text Reader

Abstract

The invention belongs to the field of gene engineering, and relates to a novel diterpene synthase from cephalotaxus plants, a nucleic acid molecule of the diterpene synthase, an expression vector containing the nucleic acid molecule, a host cell containing the vector, a preparation method of the diterpene synthase, and application of the diterpene synthase or the host cell in synthesis of diterpene compounds. The diterpenoid synthase provided by the invention can be used for efficiently synthesizing a cephalotaxane diterpenoid compound biosynthesis precursor cephalotaxene, and a new method is provided for obtaining cephalotaxane diterpenoid compounds such as cephalotaxus hainanensis lactone and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The present invention belongs to the field of genetic engineering, and specifically relates to a novel diterpene synthase derived from Cephalotaxus plants, a nucleic acid molecule thereof, an expression vector comprising the nucleic acid molecule and a host cell comprising the vector, a method for preparing the diterpene synthase, and application of the diterpene synthase or the host cell in the synthesis of diterpene compounds. Technical background:

[0002] Harringtonolide (also known as hainanolide) is a diterpene compound with a 6 / 6 / 5 / 7 tetracyclic rigid skeleton and a highly oxidized harringtonia complex structure discovered in the 1870s from Cephalotaxus genus. It includes a cycloheptatrienone structural unit and contains multiple chiral centers in the molecule. It has anti-tumor, anti-inflammatory and antiviral activities (Buta JG, Flippen JL, Lusby WR. Harringtonolide, a plant growth inhibitorytropone from Cephalotaxus harringtonia (Forbes) K. Koch. Journal of Organic Chemistry, 1978, 43 (5), 1002-1003. Sun Nanjun, Xue Zhi, Liang Xiaotian, et al. Study on the structure of Hainananolide, a new anticancer active ingredient. Acta Pharmaceutica Sinica, 1979 (1). Ni L, Zhong XH, Chen XJ, Zhang BJ, Bao MF, Cai X H. Bioactive norditerpenoids from Cephalotaxus fortuneivar.alpina and C.lanceolata. Phytochemistry, 2018, 151, 50-60.). So far, more than 80 compounds of this type have been reported ( Figure 1), collectively referred to as cephalotane-type diterpenoids (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939. Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar. alpina. Chinese Journal of Chemistry, 2022, 40(10), 1177-1184.).

[0003] At present, the cephalotaxane diterpenoid compounds are only found in Cephalotaxus plants, with limited sources and low content. Although the chemical synthesis of this type of compound has been reported, due to its complex structure and multiple chiral centers, it is difficult to synthesize, the route is long, the yield is low, and it has no commercial application value. In addition, chemical synthesis often uses toxic reagents, causing environmental pollution, etc., which limits its application. (Xu L, Wang C, Gao Z, Zhao Y M.Total Synthesis of (±)-cephanolides B and C via a Palladium-catalyzed cascade cyclization and late-stage sp3 CH bond oxidation. Journal of American Chemical Society, 2018, 140, 5653-5658. Zhang H, He H, Gao S. Asymmetric total synthesis of cephanolideA. Angewandte Chemie International Edition,2020,59,20417-20422.Zhang H,He H,Gao S.Asymmetric total synthesis of cephanolide B.Organic Chemistry Frontier,2021,8,555-559.Haider M,Sennari G,Eggert A,Sarpong R.Total synthesis of theCephalotaxus norditerpenoids(±)-cephanolides AD.Journal of AmericanChemical Society,2021,143,2710-2715.Ao Q,Zhang HJ,Zheng J,Chen X,ZhaiH.Asymmetric total synthesis of(+)-mannolide C.Angewandte ChemieInternational Edition,2021,60,21267-21271.Ren Z,Sun Z,Li Y,Fan X,Dai M,WangY,Hu of(+)-3-deoxyfortalpinoid F,(+)-fortalpinoid A,and(+)-cephinoid H.Angewandte Chemie International Edition, 2021, 60, 18572-18576. Li A, He Z, Liu B, Yang Z, Zhang Z. Stereoselective synthesis of (±)-cephanolideB. Organic Letters, 2021, 23, 9237-9240.). .

[0004] In summary, the sources of this type of compound are limited, which restricts its development and application as a drug. Biosynthesis can provide an effective means to solve this problem. However, there is still no report on its biosynthesis research. The biosynthesis of this type of compound is based on geranylgeranyl pyrophosphate (GGPP) as a precursor, which is catalyzed by diterpene synthase to generate diterpene nucleus compounds, and then catalyzed by multiple post-modification enzymes to generate Hainan quinoline lactone and its analogs. At present, the diterpene synthase responsible for this reaction has not been reported.

[0005] Therefore, the discovery and functional identification of the relevant diterpene synthases for the synthesis of diterpene nucleus compounds, the key precursors in the biosynthesis of hainan truncatula lactone and other truncatula lactone, will lay the foundation for the synthesis of hainan truncatula lactone and other truncatula lactone diterpene compounds with medicinal value using biosynthetic methods, and has potential application value. Summary of the invention

[0006] To overcome the deficiencies in the prior art, the present invention aims to provide a novel diterpene synthase, a nucleic acid molecule thereof, an expression vector comprising the nucleic acid molecule and a host cell comprising the vector, a method for preparing the diterpene synthase, and the use of the diterpene synthase or the host cell in the synthesis of diterpene compounds.

[0007] In a first aspect, the present invention provides a novel diterpene synthase having an amino acid sequence as shown in SEQ ID NO.1, or having an amino acid sequence that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:1 and has the activity of catalyzing the production of diterpene compounds.

[0008] The diterpene synthase provided by the present invention can be isolated from Cephalotaxus plants such as Torreya grandis and Cephalotaxus aubergineus.

[0009] The diterpene synthase provided by the present invention can be chemically modified and / or immobilized. The chemical modification can be selected from one or more of acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, and polyethylene glycol PEG modification.

[0010] The diterpene synthase provided by the present invention may be connected to a tag for detection and / or purification for detection or purification. The tag may be selected from one or more of His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or Profinity eXact.

[0011] The present invention also provides a truncated version of the diterpene synthase.

[0012] As a preferred embodiment, the truncated form is a truncated form of the diterpene synthase without a signal peptide, such as residues 80 to 865 of the diterpene synthase.

[0013] The truncated diterpene synthase provided by the present invention can be chemically modified and / or immobilized. The chemical modification can be selected from one or more of acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, and polyethylene glycol PEG modification.

[0014] The truncated form of the diterpene synthase provided by the present invention may be connected to a tag for detection and / or purification for detection or purification. The tag may be selected from one or more of His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or ProfinityExact.

[0015] In a second aspect, the present invention provides a nucleotide encoding the diterpene synthase described in the first aspect.

[0016] The nucleotide encoding the diterpene synthase described in the first aspect of the present invention can be cloned from Cephalotaxus plants such as Torreya grandis and Cephalotaxus truncatula.

[0017] As a specific embodiment, the nucleotide has a nucleotide sequence as shown in SEQ ID NO: 2, and the sequence is named CsCTS.

[0018] The present invention also provides nucleotides encoding the truncated version of the diterpene synthase described in the first aspect.

[0019] In a third aspect, the present invention provides a recombinant vector into which the nucleotide described in the second aspect is inserted, and / or the diterpene synthase or a truncated form of the diterpene synthase described in the first aspect is exogenously expressed.

[0020] As a preferred embodiment, the vector can be an expression vector capable of expressing the target protein in bacteria, yeast, plant or animal cells. More preferably, the vector is an expression vector capable of expressing the target protein in Escherichia coli, Pichia pastoris, Saccharomyces cerevisiae, Arabidopsis thaliana, Nicotiana benthamiana, or insect cells.

[0021] As a specific implementation scheme, the nucleic acid molecule described in the second aspect of the present invention can be connected to an expression vector by means of enzyme cutting and homologous recombination.

[0022] In a fourth aspect, the present invention provides a host cell into which the nucleotide described in the second aspect or the vector described in the third aspect is exogenously introduced. The host cell may be a bacterium, a yeast, a plant cell or an animal cell.

[0023] In a fifth aspect, the present invention provides use of the nucleotide, the vector or the host cell in preparing a diterpene synthase.

[0024] In a sixth aspect, the present invention provides a method for preparing the diterpene synthase or a truncated version of the diterpene synthase in the first aspect using the nucleotide, the vector or the host cell.

[0025] As a specific solution, the method comprises the following steps: culturing the host cell, extracting the diterpene synthase or the truncated form of the diterpene synthase, and obtaining a crude enzyme. Preferably, the method further comprises purifying the crude enzyme.

[0026] In a seventh aspect, the present invention provides use of the diterpene synthase or a truncated form of the diterpene synthase described in the first aspect in an enzymatic reaction.

[0027] As a specific embodiment, the enzymatic reaction refers to: catalyzing the cyclization reaction of the substrate geranylgeranyl pyrophosphate (GGPP).

[0028] In an eighth aspect, the present invention provides a method for preparing cephalotaxene, its analogs or derivatives thereof using the diterpene synthase, a truncated form of the diterpene synthase, the nucleotide, the vector or the host cell.

[0029] The cephalotaxene of the present invention has a structure as shown in I:

[0030]

[0031] As a specific scheme, the method comprises: utilizing the diterpene synthase or a truncated form of the diterpene synthase to carry out an enzymatic reaction with geranylgeranyl pyrophosphate (GGPP) as a substrate to generate cephalotaxene.

[0032] The analogs or derivatives of cephalotene described in the present invention specifically refer to natural diterpene compounds isolated from Cephalotane plants and having a cephalotene parent core structure, including literature (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua HM. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939) and literature (Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue J M. Cephalotane-Type Norditerpenoidsfrom Cephalotaxus fortunei var.alpina. Chinese Journal of Chemistry, 2022, 40(10), 1177-1184), all cephalotane-type diterpenoids reported in the literature, such as Hainan crude torrefaction, etc., and also include other natural diterpenoids with a cephalotene core structure that have not been reported. The analogs or derivatives of cephalotene may also refer to: analogs or derivatives thereof that have been structurally modified based on the cephalotene core.

[0033] The method of the present invention can also be: co-expressing the diterpene synthase or the truncated form of the diterpene synthase with other enzymes having biocatalytic activity to obtain analogs or derivatives thereof. The co-expression utilizes a host that can be a microorganism such as Escherichia coli, yeast, or a plant with a clear genetic background such as tobacco or Arabidopsis.

[0034] The other enzymes with biocatalytic activity can be selected from: oxidases, reductases, glycosyltransferases, methyltransferases, acyltransferases, isopentenyltransferases, etc.; the oxidase can be specifically selected from dehydrogenases, monooxygenases (such as cytochrome P450 enzymes) or dioxygenases (α-ketoglutarate-dependent dioxygenases).

[0035] The other enzymes with biocatalytic activity may be a single enzyme or a combination of multiple enzymes. Specifically, the multiple enzyme combination may be a combination of multiple enzymes with different catalytic principles and types, such as a combination of oxidase and glycosyltransferase, a combination of oxidase and methyltransferase, a combination of oxidase and acyltransferase, etc.; or may be a combination of multiple enzymes with the same catalytic principle, such as a combination of multiple enzymes of different subfamilies in cytochrome P450 enzymes, or a combination of multiple enzymes of the same subfamily in cytochrome P450 enzymes but with different primary structures.

[0036] Additional Notes

[0037] Unless otherwise specified, the scientific and technological terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The present invention may also be implemented using any methods and materials similar to or equivalent to those described herein, and specific implementation methods and preferred methods and materials are described herein without limiting the present invention in any way.

[0038] Beneficial technical effects:

[0039] The diterpene synthase of the present invention includes recombinant engineering cells and recombinant enzymes that can efficiently synthesize the biosynthetic precursor of the cephalotaxane diterpene compounds such as hainan truncatula lactone, cephalotaxene, avoiding the defects of poor stereo and regional selectivity, protection and deprotection of functional groups, long routes, high costs, and environmental pollution in chemical synthesis methods, and does not need to be extracted from plants, providing a new method for obtaining cephalotaxane diterpene compounds such as hainan truncatula lactone. In addition, the derivatization of the diterpene compound can obtain more active compounds with novel structures, providing new chemical entity molecules for the research and development of new drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 , representative 6 / 6 / 5 / 7 tetracyclic skeleton cephalane diterpenoid compounds from Cephalotaxus plants;

[0041] Figure 2 , GC-MS analysis spectra of CsCTS reaction products; a. GC spectrum of cephalotaxene (peak C); b. MS spectrum of cephalotaxene (peak C). DETAILED DESCRIPTION

[0042] The following examples are provided to further illustrate various aspects of the present invention. These examples are non-limiting and should not be construed as limiting any aspect of the present invention. The scope of protection of the present invention is limited only by the claims. Without departing from the scope of the claims, those skilled in the art may make various modifications and improvements to various aspects of the present invention, and these modifications and improvements also belong to the scope of protection of the present invention. For example, replacing the promoter and expression vector used in the examples with other promoters and expression vectors commonly used in the art is something that can be understood and implemented by those of ordinary skill in the art.

[0043] In addition, it should be noted that, unless otherwise specified, the various materials and reagents used in the following examples are commonly used materials and reagents in the art and can be obtained through conventional commercial channels; the methods used are conventional methods known to those skilled in the art.

[0044] Example 1: Cloning of CsCTS gene

[0045] 1. Extraction of total RNA and synthesis of the first strand of cDNA

[0046] Select appropriate amount of Torreya grandis stems and leaves as materials, quickly transfer them to a mortar pre-cooled with liquid nitrogen, and grind them into powder; transfer the ground powdered samples to a centrifuge tube, add 500 μL Buffer RCL / 100 mg tissue (EZNA TM Plant RNA Kit), homogenized with a vortexer and mixed by repeated pipetting; incubated at 55°C for 3 min; centrifuged at 15,000g for 5 min, transferred the supernatant to the filter column, and centrifuged at 14,000g for 2 min. Add an equal volume of BufferRCB to the filtrate and invert 5-10 times. Transfer the liquid to the RNA adsorption column and centrifuge at 10,000g for 1 min; discard the filtrate, add 400μL RWCwash Buffer to the adsorption column, and centrifuge at 10,000g for 1 min; dry the adsorption column at room temperature and elute the total RNA with 50μL ddH2O. The integrity of the total RNA was detected by 1.0% non-denaturing agarose gel electrophoresis, and the OD was measured by UV spectrophotometer. 260 / OD 280 ratio and RNA concentration. Using SMARTer TM The first-strand cDNA was synthesized using RACE cDNA amplification kit (Clontech, USA).

[0047] 2. PCR amplification of target gene fragments

[0048] According to the transcriptome information of Torreya grandis, specific primers (SEQ ID NO.3, SEQ ID NO.4) of the candidate gene CsCTS were designed, and PCR amplification was performed using KOD DNA Polymerase to obtain the full length of the CsCTS gene. The PCR product (target gene fragment) was recovered by gel, connected to the pEASY-blunt vector, transformed into Trans1-T1 competent cells, colony PCR screening was performed, and positive clones were shaken and sent for sequencing to confirm the sequence information of the candidate gene.

[0049] 2.1 PCR reaction system

[0050]

[0051] 2.2 PCR Cycle

[0052] 1) 94℃ 2min; 2) 98℃ 10sec; 3) 58℃ 15sec; 4) 68℃ 2min;

[0053] 5) to 2) 35 cycles; 6) 68℃ 5min; 7) 10℃ hold

[0054] Example 2: Expression of CsCTS gene, purification of recombinant enzyme and functional identification

[0055] 1. Construction of Rosetta-pET28a-CsCTS recombinant expression strain, induction expression of recombinase and detection

[0056] The pET-28a(+) vector contains a "T7" strong promoter and a "T7" translation initiation signal. The vector contains His tag protein sequences at both the N-terminal and C-terminal. In addition, the vector contains multiple commonly used multiple cloning restriction sites. The His tag can be added to the N-terminal or C-terminal of the target protein for fusion expression as needed.

[0057] According to the gene sequences on both sides of the multi-cloning site of the pET28a(+) vector, primers containing 17bp vector homology arms (SEQ ID NO.5, SEQ ID NO.6) were designed. The homology arms were introduced at the N-terminus and C-terminus of the target gene coding sequence (CDS) by PCR technology, and the PCR products were recovered by gel. The target gene was connected to the linearized pET28a(+) vector using homologous recombinase, and the recombinant plasmid pET28a-CsCTS was constructed. The E. coli (Transl T1) cloning host was transformed, and the positive transformants were screened by PCR, and the correctness of the reading frame was identified by sequencing. The transformants with correct sequencing were amplified and cultured, the plasmids were extracted, and the E. coli Rosetta competent cells were transformed, and the positive clones were screened by PCR. The positive transformants were stored at -80°C in 15% glycerol.

[0058] The steps of inducing expression of recombinant enzyme, extracting crude enzyme solution and detecting are as follows: 1) the positive transformants with correct sequences identified by sequencing were inoculated into LB medium containing both kanamycin (pET-28a vector carries resistance) and chloramphenicol (Rosetta host bacteria carries resistance), and cultured at 37°C and 200 rpm for 12 h; 2) the activated seed solution was inoculated into LB (kanamycin) at a ratio of 100:1. + , Chloramphenicol + ) medium, use 250mL Erlenmeyer flasks, each containing 50mL of liquid (use 500mL Erlenmeyer flasks for scale-up experiments, each containing 200mL of liquid); 3) Cultivate at 37°C and 200rpm until OD 600 ≈0.6, add IPTG with a final concentration of 0.2mM to each bottle of culture; induce the expression of the target enzyme at 18℃ and 200rpm; 4), collect the bacteria after 20h of induction culture, centrifuge at 8,000g for 5min, discard the supernatant, and wash the bacteria with ddH2O 1-2 times; 5), add 3mL / g protein extraction buffer (25mM MOPS, 1mM DTT, 10% v / v glycerol, 300mM NaCl, 1mM PMSF, pH 6.8) to the bacteria, vortex to resuspend the precipitate; 6), place the centrifuge tube in an ice bath and ultrasonically disrupt it for 15min (130w, 3s / 3s), and centrifuge at 15,000g for 30min at 4℃ to collect the supernatant, which is the crude enzyme solution.

[0059] 2. Isolation and purification of CsCTS recombinase

[0060] The Rosetta-pET28a-CsCTS recombinant expression strain was used to express the recombinant enzyme and to separate and purify it. The target gene was fused with 6×His tag, and the fusion protein containing the His tag was separated and purified using Ni-TED 6FF (Fast Flow resin) pre-packed column (Shanghai Sangon Biotechnology Co., Ltd.) affinity chromatography column and PD-10 Desalting Columns (GE Healthcare). The specific steps are as follows:

[0061] 2.1. Preparation of buffer

[0062] 1) Binding buffer: 25 mM MOPS buffer, 10% (v / v) glycerol, 300 mM NaCl, pH 6.8;

[0063] 2) Elution buffer: 25 mM MOPS, 300 mM NaCl, 10% (v / v) glycerol, 500 mM imidazole, pH 6.8;

[0064] 3) Desalting buffer: 50mM Tris-HCl, 1mM DTT, 1.5% glycerol, 50mM NaCl, 2.5mMgCl2;

[0065] 4), lysis buffer: binding buffer+1mM PMSF, pH 6.8.

[0066] 2.2 Pretreatment of Ni-TED 6FF prepacked affinity chromatography column

[0067] According to the ratio that each 1mL Ni-TED 6FF column bed can bind to the protein expressed by 2L recombinant strain culture, an affinity chromatography column of appropriate size was selected for column loading, and 10 column volumes of ddH2O, binding buffer, and elution buffer were used for elution in sequence, and finally the column was equilibrated with binding buffer.

[0068] 2.3. Preparation and loading of CsCTS recombinant enzyme crude extract

[0069] The steps of recombinant strain culture and protein induction expression are shown in 1. The induced cultured recombinant bacteria were centrifuged at 8,000g at 4°C to collect the cells, and lysis buffer was added to the cells at a ratio of 3mL / g, and the precipitate was resuspended by vortexing. After ultrasonic disruption in an ice bath for 15min (130w, 3s / 3s), the supernatant was centrifuged at 15,000g for 30min at 4°C, and the supernatant was the crude enzyme extract. The obtained crude enzyme extract was filtered with a 0.45μm filter membrane and loaded into an affinity chromatography column at a flow rate of 1mL / min.

[0070] 2.4. Elution of CsCTS recombinant enzyme

[0071] After loading, the impurities were eluted with 10 column volumes of binding buffer at a flow rate of 1 mL / min. The impurities that were not tightly bound to the column bed were eluted. When the ultraviolet absorption value of the eluent at 280 nm tended to 0, the target protein was eluted. Elution buffers with different imidazole concentrations were prepared for gradient elution of the target protein. The imidazole concentration gradient was as follows: 10 mM, 20 mM, 50 mM, 100 mM. Finally, elution buffer was used for elution. Each concentration gradient was eluted for 5 column volumes, and each flow fraction was detected by SDS-PAGE. The high-purity flow fraction containing the target protein was ultrafiltered and concentrated in an ultrafiltration centrifuge tube (30 kDa, Millipore).

[0072] 2.5. Desalting of CsCTS recombinant enzyme

[0073] The PD-10 Desalting Column was equilibrated with 10 times column volume of pre-cooled ddH2O and desalting buffer respectively. The protein concentrate obtained by ultrafiltration was slowly loaded onto the upper layer of the desalting column. After the sample completely entered the desalting column, it was eluted with desalting buffer and the eluate was received. Each 1 mL was taken as a fraction for SDS-PAGE detection. According to the elution principle of the PD-10 desalting column, the fractions were combined and diluted to an appropriate volume with desalting buffer for protein content determination.

[0074] 3. Functional identification of CsCTS recombinase

[0075] The catalytic function of recombinant CsCTS was identified using GGPP as a substrate. The reaction system was as follows: 10 μg GGPP, 0.2 mg recombinant CsCTS protein, a total reaction volume of 500 μL, reaction buffer (50 mM Tris-HCl, 1 mM DTT, 1.5% glycerol, 50 mM NaCl, 2.5 mM MgCl2), and the reaction was stopped after 12 h in a 30°C water bath. Extract with n-hexane: take 700 μL of n-hexane, vortex for 20 s, let stand for 20 s, and repeat 3 times; then, centrifuge at 15,000 g for 10 min at 4°C, collect the upper n-hexane phase; extract 3 times, collect the n-hexane extract phase, concentrate it, and make it up to 100 μL for GC-MS analysis ( Figure 2 ).

[0076] Example 3: Preparation of the diterpene product cephalotene

[0077] 1. Construction and fermentation of Cephalotene-producing engineered bacteria

[0078] 200 ng of pIRS, 200 ng of pGG and 200 ng of pET28a-CsCTS were co-transformed into E. coli BL21 (DE3). The positive transformants with correct sequences identified by sequencing were inoculated into LB containing three antibiotics (kanamycin + , Chloramphenicol + Spectinomycin + ) medium and cultured at 37°C with shaking at 200 rpm for 12 h. The activated seed solution was inoculated into TB (kanamycin) at a ratio of 100:1. + , Chloramphenicol + Spectinomycin + ) medium, select 500mL Erlenmeyer flasks, each containing 200mL of liquid, a total of 20L, and culture at 37℃ for about 2.5h until OD 600 The shaker temperature was lowered to 18°C ​​and cultured for 1 hour, and then a final concentration of 0.2 mM IPTG was added for induction for 72 hours.

[0079] 2. Preparation of Cephalotene

[0080] The recombinant bacterial culture obtained by fermentation was centrifuged at 8,000g at 4°C to collect the bacterial cells and bacterial liquid respectively. The bacterial liquid was extracted with an equal volume of ethyl acetate three times and concentrated under reduced pressure to obtain an extract. The bacterial cells were ultrasonically extracted with methanol three times, the methanol phase was collected and concentrated under reduced pressure, then dispersed with water, and then extracted with an equal volume of ethyl acetate three times, and concentrated under reduced pressure to obtain an extract. The two parts of the extract were combined for silica gel column chromatography, eluted with n-hexane, and detected by GC-MS to obtain the product cephalotene.

[0081] Example 4: Structural Identification of Cephalotene

[0082] About 10 mg of the product obtained by GC-MS analysis in Example 3 was dissolved in deuterated chloroform and analyzed by nuclear magnetic resonance spectroscopy, and its planar structure was identified as cephalotene. 195.6 mg cephalotene (719.7 μmol, 1.0 equiv) was dissolved in a mixed solvent of 3.75 mL t-BuOH and 3.75 mL H2O, and 707.5 mg K3Fe(CN)6 (2159.1 μmol, 3.0 equiv), 297.5 mg K2CO3 (2159.1 μmol, 3.0 equiv), 67.5 mg MeSO2NH2 (719.7 μmol, 1.0 equiv), 25.0 mg K2OsO2(OH)4 (67.8 μmol, 10.0 mol%) and 100.0 mg (DHQD)2PHAL (128.5 μmol, 0.20 mol%) were added. The mixture was stirred at room temperature (23°C) for 2 d (the reaction process was monitored in real time), and an excess of Na2S2O3 was added and the reaction was terminated by stirring for 10 min. The reaction solution was extracted with CH2Cl2 for 3 times, the combined extracts were dried over Na2SO4, concentrated to dryness under reduced pressure, dissolved with ethyl acetate, weighed after evaporation, and chromatographed on a silica gel column, with the elution phase being petroleum ether: ethyl acetate = 4 / 1. The reaction product was detected by GC-MS. The prepared dihydroxylated product was crystal cultured under the conditions of n-hexane: ethyl acetate 10:1, and the obtained single crystal was further confirmed by X-ray single crystal diffraction analysis to determine its structure and stereo configuration.

[0083]

[0084] Cephalotene: [α] D 20 -10.8 (c=0.50, CH2Cl2).EI-MS: [M] + m / z=272.UV(MeOH)λ max(logε)203(1.27), 240(0.55) nm. IR ν max 2950, 2924, 2869, 1456, 144l, 1376, 1038 cm -1 . 1 H NMR(CDCl3, 600 MHz), δ H : 1.82(2H, t, 9.6 Hz, H-1), 2.83(m, H-2), 5.41(d, 8.4 Hz, H-4), 1.86(m, H-5α), 2.24(m, H-5β), 1.36(m, H-6α), 1.48(m, H-6β), 1.47(m, H-8α), 0.84(m, H-8β), 1.26(m, H-9α), 1.61(dt, 14.4, 3.6, H-9β), 1.80(m, H-11), 1.15(m, H-12α), 0.95(m, H-12β), 1.46(m, H-13α), 1.79(m, H-13β), 2.30(m, H-14), 1.96(2H, m, H-15, H-16), 0.86(3H, s, H-17), 0.74(3H, d, 6.6, H-18), 0.97(3H, s, H-19), 1.66(3H, s, H-20). 13 C NMR(CDCl3, 150 MHz), δ C : 37.8(C-1), 43.5(C-2), 141.0(C-3), 125.8(C-4), 22.9(C-5), 43.2(C-6), 33.8(C-7), 31.6(C-8), 32.0(C-9), 34.4(C-10), 29.4(C-11), 26.0(C-12), 24.1(C-13), 34.3(C-14), 48.2(C-15), 53.7(C-16), 26.5(C-17), 16.6(C-18), 26.4(C-19), 24.5(C-20).

[0085] 3,4-Dihydroxy-cephalotene: [α] D 20 -21.8(c = 0.44, MeOH); EI-MS: m / z = 306 [M] + ; IR ν max 3406, 2949, 2925, 2871, 1642, 1466, 1375, 1080 cm -1 . 1 H NMR(CDCl3, 600 MHz), δ H: 2.18 (m, H-1α), 1.72 (m, H-1β), 2.42 (m, H-2), 3.61 (dd, 5.2, 1.6 Hz, H-4), 1.65 (m, H-5α), 1.76 (m, H-5β), 0.95 (m, H-6α), 2.00 (m, H-6β), 1.21 (m, H-8α), 1.07 (m, H-8β), 1.19 (m, H-9α), 1.48 (m, H-9β), 1.66 (m, H-11), 1.73 (m, H-12α), 1.21 (m, H-12β), 1.53 (m, H-13α), 1.73 (m, H-13β), 1.72 (m, H-14), 1.87 (t, 8.0, H-15), 1.51 (m, H-16), 0.84 (3H, s, H-17), 0.72 (3H, d, 6.6, H-18), 0.93 (3H, s, H-19), 1.11 (3H, s, H-20). 13 13C NMR (CDCl3, 150 MHz), δ C : 37.2 (C-1), 43.1 (C-2), 78.1 (C-3), 75.5 (C-4), 24.6 (C-5), 32.3 (C-6), 33.2 (C-7), 33.7 (C-8), 31.6 (C-9), 34.0 (C-10), 30.8 (C-11), 25.8 (C-12), 22.6 (C-13), 33.7 (C-14), 48.7 (C-15), 50.7 (C-16), 24.6 (C-17), 16.1 (C-18), 28.9 (C-19), 20.6 (C-20). Single crystal data: C 20 H 34 O2, 0.375(H2O) (M = 313.23 g / mol): triclinic, space group P1 (no.1), α = 89.7661(4)°, β = 83.0676(4)°, γ = 80.7903(4)°, Z = 8, T = 100.00(10) K, μ(Cu Kα) = 0.553 mm -1 , Dcalc = 1.132 g / cm 3 , 128486 reflections measured (7.436° ≤ 2Θ ≤ 144.252°), 27337 unique (R int = 0.0312, R sigma=0.0260)which were used in all calculations.Thefinal R1 was 0.0364(I>2σ(I))and wR2 was 0.0941(all data)。

Claims

1. A diterpene synthase, characterized in that The amino acid sequence is as shown in SEQ ID NO.1, or an amino acid sequence that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:1 and has the activity of catalyzing the production of diterpene compounds.

2. The diterpene synthase according to claim 1, characterized in that The diterpene synthase is chemically modified and / or immobilized; Preferably, the chemical modification is selected from one or more of acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, and polyethylene glycol (PEG) modification.

3. The diterpene synthase according to claim 1, characterized in that The diterpene synthase is connected to a tag for detection and / or purification; Preferably, the tag is selected from one or more of His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or ProfinityeXact.

4. A truncated form of the diterpene synthase according to claim 1.

5. The truncated form of diterpene synthase according to claim 4, characterized in that It is a truncated version of the diterpene synthase minus the signal peptide, preferably the 80th to 865th residues of the amino acid sequence shown in SEQ ID NO.

1.

6. The truncated form of diterpene synthase according to claim 4 or 5, characterized in that The truncated form of the diterpene synthase is chemically modified and / or immobilized; Preferably, the chemical modification is selected from one or more of acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, and polyethylene glycol (PEG) modification.

7. The truncated form of diterpene synthase according to claim 4 or 5, characterized in that The truncated form of the diterpene synthase is connected to a tag for detection and / or purification; Preferably, the tag is selected from one or more of His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or ProfinityeXact.

8. A nucleotide, characterized in that It encodes the diterpene synthase according to any one of claims 1 to 3, and preferably has the nucleotide sequence shown in SEQ ID NO: 2; Alternatively, it encodes a truncated form of the diterpene synthase according to any one of claims 4 to 7.

9. A carrier, characterized in that wherein the nucleotide of claim 8 is inserted, and / or the diterpene synthase of any one of claims 1 to 3 or the truncated form of the diterpene synthase of any one of claims 4 to 7 can be exogenously expressed; Preferably, the vector is an expression vector capable of expressing the target protein in bacteria, yeast, plant or animal cells; More preferably, the vector is an expression vector capable of expressing the target protein in Escherichia coli, Pichia pastoris, Saccharomyces cerevisiae, Arabidopsis thaliana, Nicotiana benthamiana, or insect cells.

10. A host cell into which the nucleotide according to claim 8 or the vector according to claim 9 has been exogenously introduced; Preferably, the host cell is a bacterium, a yeast, a plant cell or an animal cell.

11. Use of the nucleotide according to claim 8, the vector according to claim 9 or the host cell according to claim 10 in preparing a diterpene synthase.

12. A method for preparing the diterpene synthase according to any one of claims 1 to 3 or a truncated form of the diterpene synthase according to any one of claims 4 to 7 using the nucleotide according to claim 8, the vector according to claim 9 or the host cell according to claim 10.

13. The method according to claim 12, characterized in that The method comprises the following steps: culturing the host cell according to claim 10, extracting the diterpene synthase or the truncated form of the diterpene synthase to obtain a crude enzyme; Preferably, the method further comprises purifying the crude enzyme.

14. Use of the diterpene synthase according to any one of claims 1 to 3 or a truncated form of the diterpene synthase according to any one of claims 4 to 7 in an enzymatic reaction.

15. The use according to claim 14, characterized in that: The enzymatic reaction refers to: catalyzing the substrate geranylgeranyl pyrophosphate (GGPP) to undergo a cyclization reaction.

16. A method for preparing cephalosin, its analogs or derivatives thereof using the diterpene synthase according to any one of claims 1 to 3, the truncated form of the diterpene synthase according to any one of claims 4 to 7, the nucleotide according to claim 8, the vector according to claim 9 or the host cell according to claim 10; The trihalomethane has a structure as shown in I:

17. The method according to claim 16, characterized in that The method comprises: utilizing the diterpene synthase or the truncated form of the diterpene synthase to carry out an enzymatic reaction with geranylgeranyl pyrophosphate (GGPP) as a substrate to generate cephalotaxene.

18. The method according to claim 16, characterized in that The method comprises: co-expressing the diterpene synthase or the truncated form of the diterpene synthase with other enzymes having biocatalytic activity to obtain analogs or derivatives thereof; Preferably, the other enzymes having biocatalytic activity are selected from one or more of: oxidase, reductase, glycosyltransferase, methyltransferase, acyltransferase, isopentenyltransferase.